Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 4-6 hours; maximum 12 g/day.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic